Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Implantica

52.30 SEK

-0.95 %

Less than 1K followers

IMP A SDB

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
-0.95 %
+4.70 %
-11.80 %
+21.91 %
+52.03 %
+52.92 %
+24.97 %
-53.68 %
-45.84 %

Implantica operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes implantable medical instruments, which are also used for the treatment of diseases affecting the esophagus. In addition to the main business, related ancillary services are offered, particularly focused on eHealth. The business is operated globally with the largest presence in North America and Europe.

Read more
Market cap
61.88B SEK
Turnover
1.72M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
25.2.
2026

Annual report '25

All
Webcasts
Press releases
ShowingAll content types
Press release11/25/2025, 7:00 AM

Implantica: RefluxStop® "Best in Class" at Japan Foregut Conference as 5-Year Data and Extensive Safety Cohort is Presented to 120 Leading Surgeons

Implantica
Press release11/11/2025, 7:00 AM

Implantica: RefluxStop® takes center stage at 2025 European Foregut Society meeting

Implantica
Implantica, Webcast, Q3'25
Webcast10/31/2025, 2:00 PM

Implantica, Webcast, Q3'25

Implantica

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Regulatory press release10/31/2025, 7:00 AM

Implantica publishes Interim Report January - September 2025 (Q3)

Implantica
Press release10/27/2025, 8:30 AM

Implantica presents the third quarter 2025 on October 31 at 15:00 CET

Implantica
Press release10/13/2025, 8:30 AM

Implantica completes FDA 100-Day Meeting for RefluxStop® PMA application

Implantica
Press release10/6/2025, 6:00 AM

Implantica Successfully Completes MDSAP Recertification Audit

Implantica
Press release9/25/2025, 6:00 AM

Implantica steps up to close the treatment gap with RefluxStop® as main device competitor exits Europe and the UK

Implantica
Press release9/24/2025, 6:00 AM

Implantica announces U.S. FDA has provided feedback on the final RefluxStop® PMA submission, Module 3

Implantica
Press release9/17/2025, 6:00 AM

Implantica's RefluxStop® sparks strong excitement at the American Foregut Society meeting, ahead of pending US FDA approval

Implantica
Regulatory press release9/10/2025, 7:00 PM

Implantica announces the payment of share rewards based on the AGM approved share-based incentive program as a directed share issue of own shares of the company without consideration

Implantica
Press release9/10/2025, 6:00 AM

Implantica ramps-up production with 10,000 RefluxStop® units in preparation for U.S. launch, pending FDA PMA approval

Implantica
Implantica, Audiocast, Q2'25
Webcast8/14/2025, 1:00 PM

Implantica, Audiocast, Q2'25

Implantica
Regulatory press release8/14/2025, 6:00 AM

Implantica publishes Interim Report January - June 2025 (Q2)

Implantica
Press release8/13/2025, 6:00 AM

Implantica finishes new multi-cavity production tool for RefluxStop® to support manufacturing ramp-up in the U.S. pending FDA approval

Implantica
Press release8/7/2025, 11:05 AM

Implantica presents the second quarter 2025 on August 14 at 15:00 CEST

Implantica
Press release8/7/2025, 6:00 AM

Implantica announces second publication of groundbreaking 5-year results from the landmark RefluxStop® clinical study

Implantica
Press release7/1/2025, 6:00 AM

Implantica announces publication of the landmark RefluxStop® 5-year clinical study results demonstrating excellent long-term success

Implantica
Press release6/24/2025, 6:00 AM

Implantica submits the last and final module 3 of the FDA PMA Application for RefluxStop® for US market approval

Implantica
Press release6/17/2025, 6:00 AM

Implantica announces successful UK RefluxStop™ Users Meeting addressing growing demand after the final and positive UK NICE recommendations on use of RefluxStop in NHS public hospitals

Implantica
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.